Investigational Drug Information for Preladenant
What is the development status for investigational drug Preladenant?
Preladenant is an investigational drug.
There have been 13 clinical trials for Preladenant.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 6th 2010.
The most common disease conditions in clinical trials are Parkinson Disease, Movement Disorders, and Dyskinesias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].
Summary for Preladenant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 603 |
| WIPO Patent Applications | 182 |
| Japanese Patent Applications | 55 |
| Clinical Trial Progress | Phase 3 (2010-07-06) |
| Vendors | 67 |
Recent Clinical Trials for Preladenant
| Title | Sponsor | Phase |
|---|---|---|
| Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | Merck Sharp & Dohme Corp. | Phase 1 |
| A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) | Merck Sharp & Dohme Corp. | Phase 1 |
| A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512) | Merck Sharp & Dohme Corp. | Phase 1 |
Clinical Trial Summary for Preladenant
Top disease conditions for Preladenant
Top clinical trial sponsors for Preladenant
US Patents for Preladenant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Preladenant Development Update, Patent Status, and Market Projection
Preladenant, also known as SCH 420814, is an investigational adenosine A2A receptor antagonist developed primarily by Schering-Plough and later Merck for Parkinson's disease. Merck discontinued the program after Phase III studies failed to show a significant improvement in motor symptoms or OFF time compared with placebo. Preladenant has no FDA approval, no established commercial market, no Orange Book listing, and no current branded or generic launch pathway. Its near-term market projection is therefore zero unless another sponsor revives development under a new clinical and regulatory strategy.
What is preladenant and what was it developed to treat?
Preladenant is a selective adenosine A2A receptor antagonist intended for patients with Parkinson's disease experiencing motor fluctuations despite levodopa-based therapy.
A2A receptors are concentrated in the striatum and interact with dopaminergic signaling in motor-control pathways. The development rationale was that blocking A2A receptors could improve motor function without directly increasing dopamine exposure. This mechanism differed from dopamine agonists and monoamine oxidase-B inhibitors, which were already established Parkinson's disease treatments.
| Attribute | Preladenant |
|---|---|
| Generic name | Preladenant |
| Development code | SCH 420814 |
| Mechanism | Selective adenosine A2A receptor antagonist |
| Primary indication | Parkinson's disease with motor fluctuations |
| Principal developers | Schering-Plough; Merck after the 2009 merger |
| Clinical status | Development discontinued |
| FDA approval | None |
| Commercial product | None |
| Orange Book status | No FDA-approved product listing identified |
| Current market status | No active commercial market |
Preladenant was designed as an oral small molecule for use alongside levodopa. The intended commercial position was adjunctive treatment for patients experiencing wearing-off or other motor complications.
What was the clinical development history of preladenant?
Preladenant advanced through mid- and late-stage Parkinson's disease studies but did not establish efficacy sufficient for registration.
Development timeline
| Period | Development event |
|---|---|
| Early development | Schering-Plough advanced preladenant as a selective A2A antagonist |
| 2009 | Merck acquired Schering-Plough and inherited the program |
| 2010-2012 | Phase II and Phase III studies evaluated adjunctive use in Parkinson's disease |
| 2012 | Late-stage clinical results failed to meet key efficacy objectives |
| 2013 onward | Merck discontinued further development |
| Current status | No active clinical development or regulatory filing |
The late-stage program evaluated preladenant in patients receiving levodopa who experienced motor fluctuations. The principal endpoints generally focused on change in daily OFF time, motor function, and tolerability.
ClinicalTrials.gov records identified preladenant studies in Parkinson's disease, including trials assessing patients with motor fluctuations and patients receiving dopaminergic therapy. The program's main weakness was lack of a consistent, clinically meaningful separation from placebo on the motor endpoints needed to support approval.
Why did Merck discontinue preladenant?
Merck discontinued preladenant because Phase III studies did not demonstrate the required efficacy benefit over placebo.
The failure was clinically important for three reasons:
- The target population had a measurable and regulatorily relevant endpoint, daily OFF time.
- Existing adjunctive therapies provided an active commercial and clinical comparator environment.
- The A2A mechanism did not translate into a sufficiently reliable improvement in motor fluctuations in the studied regimen.
The development outcome also reduced the value of preladenant's remaining patent life. A Parkinson's disease program that fails after Phase III requires substantial additional investment, including possible dose redesign, patient-selection analysis, new trials, and a revised regulatory strategy. Merck did not pursue that path publicly.
What is the FDA regulatory status of preladenant?
Preladenant has no FDA approval and no publicly established FDA application for marketing authorization.
| FDA-related question | Status |
|---|---|
| Approved indication | None |
| NDA approval | None identified |
| FDA label | None |
| REMS requirement | None |
| FDA exclusivity | None |
| Orange Book listing | None |
| Approved dosage form | None |
| Generic approval pathway | None |
Because preladenant was never approved, it did not receive FDA five-year new chemical entity exclusivity, three-year clinical investigation exclusivity, or pediatric exclusivity. The absence of approval also means that generic manufacturers cannot file an ANDA against a preladenant reference product.
What patents protect preladenant?
Publicly available development information confirms that preladenant was protected through pharmaceutical patent filings and related intellectual-property rights, but the commercial importance of those rights declined sharply after clinical discontinuation.
The relevant patent categories would have included:
- Composition-of-matter claims covering preladenant and related A2A antagonist compounds.
- Pharmaceutical-composition claims covering oral formulations.
- Method-of-treatment claims for Parkinson's disease and motor fluctuations.
- Potential claims covering dosing regimens, combinations with levodopa, and other dopaminergic treatments.
- Manufacturing and intermediate claims for producing the active pharmaceutical ingredient.
A complete patent-family analysis requires a verified search of national patent registers and assignment records. The available public development record does not support a reliable statement of a single controlling patent number, expiration date, or surviving patent family for all jurisdictions. Patent expiry therefore cannot be stated accurately as one global date.
Does preladenant have formulation or method-of-use protection?
Preladenant's development strategy likely relied on multiple layers of protection beyond the basic molecule. Formulation patents could have covered oral tablets, solid-state forms, excipients, or release profiles. Method-of-use patents could have covered treatment of Parkinson's disease, reduction of OFF time, or combination therapy with levodopa.
Those rights would have had limited practical value without regulatory approval. In the United States, an unapproved method-of-use patent does not create an Orange Book-based ANDA barrier. It can still support litigation or licensing in other contexts, but there is no approved reference product against which a generic applicant could certify.
When does preladenant lose exclusivity?
Preladenant has no active FDA regulatory exclusivity because it was never approved. Patent exclusivity, if any claims remain enforceable, depends on the specific patent family, filing date, terminal disclaimers, patent-term adjustment, maintenance fees, and jurisdiction.
The commercial exclusivity position is therefore:
| Exclusivity type | Status |
|---|---|
| FDA NCE exclusivity | Never awarded |
| FDA orphan exclusivity | No approved orphan indication identified |
| Pediatric exclusivity | None identified |
| Orange Book patent term | Not applicable |
| Composition-of-matter patent term | Family-specific; no single verified date |
| Current blocking position | No demonstrated U.S. commercial block |
The practical loss of exclusivity occurred when Merck discontinued development. That event eliminated the prospect of a conventional branded launch even if certain patents remained in force.
Which companies are challenging preladenant?
No active Paragraph IV challenger landscape exists because preladenant has no approved U.S. reference product and no Orange Book-listed patents.
| Challenger category | Status |
|---|---|
| ANDA applicants | None publicly identified |
| Paragraph IV certifications | None applicable |
| Biosimilar applicants | Not applicable |
| Patent litigation against generic companies | None identified |
| Authorized generic | None |
| Competing A2A antagonist challenger | No direct preladenant challenger |
Preladenant is a small molecule, not a biologic. Biosimilar risk is therefore irrelevant. Any future follow-on product would likely use a conventional small-molecule regulatory pathway, but the absence of an approved reference product would complicate an ordinary ANDA strategy.
What patent litigation affects preladenant?
No material public patent litigation affecting a marketed preladenant product has been identified.
The litigation profile is structurally limited:
- No approved product generated Orange Book patent litigation.
- No Paragraph IV case could proceed against an approved reference product.
- No commercial launch created damages exposure for the sponsor.
- No settlement agreement with generic manufacturers is publicly associated with preladenant.
- No biosimilar litigation is relevant.
Any historical patent disputes involving the broader A2A antagonist field would not automatically affect preladenant's own development rights or patent validity.
What licensing deals involve preladenant?
The principal corporate transaction associated with preladenant was Merck's acquisition of Schering-Plough in 2009. Preladenant became part of Merck's development portfolio through that transaction.
No separate major out-licensing, co-development, or commercialization agreement for preladenant has been publicly established in the core development record. The acquisition transferred program ownership but did not result in a commercial launch.
| Transaction type | Publicly established status |
|---|---|
| Schering-Plough to Merck portfolio transfer | Yes, through the 2009 merger |
| Out-license to a third-party pharmaceutical company | Not identified |
| Co-development agreement | Not identified |
| Regional commercialization deal | Not identified |
| Post-discontinuation asset sale | Not identified |
How strong was the preladenant patent estate?
The patent estate was commercially weak despite the likely presence of composition, formulation, and use claims.
Patent strength has two dimensions:
- Legal scope and remaining term.
- Commercial value after clinical and regulatory failure.
Preladenant's commercial patent strength was reduced by the second factor. Even a strong composition patent cannot support a conventional product launch without positive clinical data and regulatory approval. The failure of Phase III studies also limits the value of method-of-use claims directed to the studied Parkinson's disease population.
The estate may still have had residual value for:
- Academic or translational research.
- Combination studies with newer Parkinson's therapies.
- Repositioning in another neurologic indication.
- Licensing of chemical matter or A2A pharmacology.
- Use as a reference compound in CNS drug discovery.
There is no public evidence that these opportunities produced a new development program.
How does preladenant compare with competing Parkinson's disease treatments?
Preladenant entered a competitive adjunctive-treatment market that included established drugs and other mechanisms.
| Therapy class | Representative products | Commercial position relative to preladenant |
|---|---|---|
| Levodopa/carbidopa | Sinemet and generics | Standard symptomatic treatment |
| Dopamine agonists | Pramipexole, ropinirole, rotigotine | Established adjunctive therapies |
| MAO-B inhibitors | Rasagiline, selegiline, safinamide | Established motor-fluctuation therapies |
| COMT inhibitors | Entacapone, opicapone | Established levodopa-extending therapies |
| Amantadine products | Gocovri and generic amantadine | Used for dyskinesia and related symptoms |
| A2A antagonists | Istradefylline | Competing mechanism with U.S. approval |
| Preladenant | SCH 420814 | Discontinued, no market presence |
Istradefylline became the main commercial validation of the A2A antagonist class in Parkinson's disease, but its approval did not rescue preladenant. Differences in receptor pharmacology, dosing, trial design, patient selection, and efficacy signal prevented class-level success from translating directly to preladenant.
What is the market projection for preladenant?
The base-case market projection is zero revenue from direct product sales.
| Scenario | Probability assessment | Market implication |
|---|---|---|
| No further development | Base case | No product revenue |
| Academic or translational revival | Low | Limited licensing or research value |
| New sponsor restarts Parkinson's program | Low | Multi-year Phase II and Phase III investment required |
| Development in another indication | Low | New clinical package and uncertain differentiation |
| Generic or follow-on launch | Not applicable currently | No approved reference product |
A commercial revival would require a new sponsor to solve several problems:
- Reproduce a clinically meaningful motor benefit.
- Identify a responsive patient subgroup.
- Establish a differentiated safety and tolerability profile.
- Compete against approved adjunctive treatments.
- Confirm sufficient remaining patent protection or obtain new use and formulation rights.
- Fund a full regulatory program after a previous Phase III failure.
The revenue opportunity for a successful A2A antagonist in Parkinson's disease is real, but it belongs to the class rather than to preladenant specifically. Preladenant has no current sales base, no approved label, and no active commercial infrastructure.
What generic entry risks exist for preladenant?
Conventional generic-entry risk is currently immaterial. The key issue is regulatory absence, not patent expiry.
If preladenant were revived and approved, future competitors could challenge:
- Composition claims.
- Polymorph or salt claims.
- Tablet and formulation claims.
- Dosing-regimen claims.
- Combination-treatment claims.
- Manufacturing-process claims.
A revived product could receive new patents or regulatory exclusivity tied to a new indication or formulation. Those protections would depend on the scope of the new clinical package and would not automatically restore the original development program's value.
Key Takeaways
- Preladenant, or SCH 420814, is a discontinued A2A receptor antagonist for Parkinson's disease.
- Merck stopped development after Phase III studies failed to demonstrate adequate efficacy.
- The compound has no FDA approval, NDA, Orange Book listing, or commercial product.
- No Paragraph IV challenge, generic litigation, biosimilar risk, or settlement agreement is associated with an approved preladenant product.
- Patent value is limited by the absence of regulatory approval and the lack of a current commercial program.
- The base-case market projection is zero direct product revenue.
- Any revival would require a new clinical strategy, substantial investment, and differentiation from approved Parkinson's disease adjunctive therapies.
FAQs
Is preladenant still being developed for Parkinson's disease?
No active clinical development program has been publicly established. Merck discontinued the program after unsuccessful late-stage studies.
Is preladenant the same as istradefylline?
No. Both target adenosine A2A receptors, but they are different molecules developed under separate programs. Istradefylline received FDA approval for OFF episodes in Parkinson's disease; preladenant did not.
Can a generic company launch preladenant in the United States?
There is no conventional ANDA launch pathway because preladenant has no FDA-approved reference product. A future sponsor would need to address the applicable regulatory pathway rather than rely on an Orange Book generic filing.
Does preladenant have biosimilar competition?
No. Preladenant is a small-molecule drug candidate, not a biologic. Biosimilar rules do not apply.
Could preladenant be revived for another neurologic indication?
A revival is technically possible but commercially unlikely without new efficacy evidence, a defined responder population, and defensible intellectual-property protection. The prior Phase III failure makes a new development program materially more difficult.
References
-
ClinicalTrials.gov. (n.d.). Studies of preladenant in Parkinson's disease. U.S. National Library of Medicine.
-
Merck & Co., Inc. (2013). Annual report and research and development pipeline disclosures. Merck & Co.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Schering-Plough Corporation. (2008). Annual report and pharmaceutical research pipeline disclosures. Schering-Plough Corporation.
-
Pinna, A. (2014). Adenosine A2A receptor antagonists in Parkinson's disease. F1000Prime Reports, 6, ?
More… ↓
